These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 7512323)

  • 1. Reappraisal of in situ immunophenotypic analysis of psoriasis skin: interaction of activated HLA-DR+ immunocompetent cells and endothelial cells is a major feature of psoriatic lesions.
    de Boer OJ; van der Loos CM; Hamerlinck F; Bos JD; Das PK
    Arch Dermatol Res; 1994; 286(2):87-96. PubMed ID: 7512323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of HLA-DR molecules by keratinocytes, and presence of Langerhans cells in the dermal infiltrate of active psoriatic plaques.
    Gottlieb AB; Lifshitz B; Fu SM; Staiano-Coico L; Wang CY; Carter DM
    J Exp Med; 1986 Oct; 164(4):1013-28. PubMed ID: 2428913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of cyclosporine A inhibition of antigen-presenting activity in uninvolved and lesional psoriatic epidermis.
    Cooper KD; Baadsgaard O; Ellis CN; Duell E; Voorhees JJ
    J Invest Dermatol; 1990 May; 94(5):649-56. PubMed ID: 2324521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymphocytes and macrophages of the epidermis and dermis in lesional psoriatic skin, but not epidermal Langerhans cells, are depleted by treatment with cyclosporin A.
    Gupta AK; Baadsgaard O; Ellis CN; Voorhees JJ; Cooper KD
    Arch Dermatol Res; 1989; 281(4):219-26. PubMed ID: 2673064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD69, HLA-DR and the IL-2R identify persistently activated T cells in psoriasis vulgaris lesional skin: blood and skin comparisons by flow cytometry.
    Ferenczi K; Burack L; Pope M; Krueger JG; Austin LM
    J Autoimmun; 2000 Feb; 14(1):63-78. PubMed ID: 10648117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The development of manifest psoriatic lesions is linked with the appearance of ICAM-1 positivity on keratinocytes.
    Paukkonen K; Naukkarinen A; Horsmanheimo M
    Arch Dermatol Res; 1995; 287(2):165-70. PubMed ID: 7763088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response of murine and normal human skin to injection of allogeneic blood-derived psoriatic immunocytes: detection of T cells expressing receptors typically present on natural killer cells, including CD94, CD158, and CD161.
    Nickoloff BJ; Wrone-Smith T; Bonish B; Porcelli SA
    Arch Dermatol; 1999 May; 135(5):546-52. PubMed ID: 10328195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fc gamma-receptors and HLA-DR antigens on endothelial cells in psoriatic skin lesions.
    Bjerke JR; Livden JK; Matre R
    Acta Derm Venereol; 1988; 68(4):306-11. PubMed ID: 2459875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dermal injection of immunocytes induces psoriasis.
    Wrone-Smith T; Nickoloff BJ
    J Clin Invest; 1996 Oct; 98(8):1878-87. PubMed ID: 8878440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early inflammatory changes in the "perilesional skin" of psoriatic plaques: is there interaction between dendritic cells and keratinocytes?
    Komine M; Karakawa M; Takekoshi T; Sakurai N; Minatani Y; Mitsui H; Tada Y; Saeki H; Asahina A; Tamaki K
    J Invest Dermatol; 2007 Aug; 127(8):1915-22. PubMed ID: 17446902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psoriatic epidermal cells demonstrate increased numbers and function of non-Langerhans antigen-presenting cells.
    Baadsgaard O; Gupta AK; Taylor RS; Ellis CN; Voorhees JJ; Cooper KD
    J Invest Dermatol; 1989 Feb; 92(2):190-5. PubMed ID: 2645367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistopathologic studies in the development of psoriatic lesion influenced by gamma-interferon and the producing cells.
    Kaneko F; Suzuki M; Takiguchi Y; Itoh N; Minagawa T
    J Dermatol Sci; 1990 Nov; 1(6):425-34. PubMed ID: 2126953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of HLA-DR antigen in skin from patients with psoriasis.
    Morhenn VB; Abel EA; Mahrle G
    J Invest Dermatol; 1982 Feb; 78(2):165-8. PubMed ID: 6173446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peptidoglycan and peptidoglycan-specific Th1 cells in psoriatic skin lesions.
    Baker BS; Laman JD; Powles A; van der Fits L; Voerman JS; Melief MJ; Fry L
    J Pathol; 2006 Jun; 209(2):174-81. PubMed ID: 16493599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In situ demonstration of CD40- and CD154-positive cells in psoriatic lesions and keratinocyte production of chemokines by CD40 ligation in vitro.
    Pasch MC; Timár KK; van Meurs M; Heydendael VM; Bos JD; Laman JD; Asghar SS
    J Pathol; 2004 Jul; 203(3):839-48. PubMed ID: 15221944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin.
    Piskin G; Sylva-Steenland RM; Bos JD; Teunissen MB
    J Immunol; 2006 Feb; 176(3):1908-15. PubMed ID: 16424222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells.
    Abrams JR; Kelley SL; Hayes E; Kikuchi T; Brown MJ; Kang S; Lebwohl MG; Guzzo CA; Jegasothy BV; Linsley PS; Krueger JG
    J Exp Med; 2000 Sep; 192(5):681-94. PubMed ID: 10974034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunologic mechanisms in psoriasis.
    Gottlieb AB
    J Am Acad Dermatol; 1988 Jun; 18(6):1376-80. PubMed ID: 3290292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical markers for arthritis in psoriasis.
    Veale DJ; Barnes L; Rogers S; FitzGerald O
    Ann Rheum Dis; 1994 Jul; 53(7):450-4. PubMed ID: 7944617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retinoic acid upregulates human Langerhans cell antigen presentation and surface expression of HLA-DR and CD11c, a beta 2 integrin critically involved in T-cell activation.
    Meunier L; Bohjanen K; Voorhees JJ; Cooper KD
    J Invest Dermatol; 1994 Dec; 103(6):775-9. PubMed ID: 7798614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.